Agios Pharmaceuticals (AGIO) Receivables (2014 - 2026)

Agios Pharmaceuticals' Receivables history runs 12 years deep, the most recent figure standing at $32.3 million for Q1 2026.

• Quarterly Receivables rose 382.42% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 382.42% YoY) and the FY2025 annual result came in at $21.2 million, up 157.41% from the prior year.
• Receivables was $32.3 million for Q1 2026 at Agios Pharmaceuticals, up from $21.2 million in the prior quarter.
• Across five years, Receivables topped out at $32.3 million in Q1 2026 and bottomed at $1.5 million in Q1 2022.
• A 5-year average of $8.2 million and a median of $6.2 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables sank 57.94% — and 2026, when it surged 382.42%.
• Agios Pharmaceuticals' Receivables stood at $4.4 million in 2022, then gained by 27.38% to $5.6 million in 2023, then soared by 46.23% to $8.2 million in 2024, then soared by 157.41% to $21.2 million in 2025, then surged by 52.52% to $32.3 million in 2026.
• Business Quant data shows AGIO's Receivables at $32.3 million in Q1 2026, $21.2 million in Q4 2025, and $10.1 million in Q3 2025.